Loading clinical trials...

Clinical Trial of TQB2922 Injection (Subcutaneous Injection) in Patients With Advanced Cancers | Clinical Trials | Clareo Health

RECRUITINGPHASE1

Clinical Trial of TQB2922 Injection (Subcutaneous Injection) in Patients With Advanced Cancers

A Phase I Clinical Study to Evaluate The Safety and Pharmacokinetics of TQB2922 Injection (Subcutaneous Injection) in Patients With Advanced Cancers

NCT07260708•Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.

View on ClinicalTrials.gov

Summary

This is a Phase I clinical study aimed at evaluating the safety and pharmacokinetics of TQB2922 subcutaneous injection in patients with advanced cancers.

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Subjects voluntarily joined this study, signed the informed consent form, and had good compliance；
•18-75 yeas old；
•Eastern Cooperative Oncology Group Performance Status (ECOG) score: 0-1;
•Expected survival of more than 12 weeks；
•Histologically or cytologically diagnosed with advanced non-squamous non-small cell lung cancer
•Subjects in the monotherapy introduction stage need to have received standard treatment or lack effective treatment.
•There must be at least one measurable lesion within the radiotherapy area that can be clearly classified as progressive according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST1.1) criteria.
•Major organs are functioning well；
•Female and male subjects of childbearing potential should agree to practice contraception for the duration of the study and for 6 months after the end of the study.

Exclusion Criteria

•Current concomitant presence of other malignancies within 5 years prior to the first dose；
•At the time of initiating the study of treatment, the adverse reactions caused by previous anti-tumor treatments failed to recover to a CTCAE 5.0 score of grade 1 or below.
•Patients who had received major surgical treatment within 4 weeks prior to the first study, had obvious traumatic injuries, or were expected to undergo major surgery during the study treatment period, or had long-term unhealed wounds or fractures.
•Hyperactive or venous thrombosis events occurred within 6 months before the first administration;
•Major cardiovascular diseases;
•Active hepatitis
•Those with a history of psychotropic drug abuse who are unable to quit or have mental disorders.
•There was an active infection (≥ Common Terminology Criteria for Adverse Events version 5.0 (CTCAE5.0) score of grade 2) within 2 weeks before the first administration;
•Patients with renal failure requiring hemodialysis or peritoneal dialysis;
•Patients who have a history of immune deficiency.
+5 more criteria

Locations (11)

Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, China

Henan Cancer Hospital

Zhengzhou, Henan, China

The First Affiliated Hospital of Zhengzhou University

Zhengzhou, Henan, China

Hunan Cancer Hospital

Changsha, Hunan, China

Nanjing Drum Tower Hospital

Nanjing, Jiangsu, China

The First Affiliated Hospital of Nanchang University

Nanchang, Jiangxi, China

Affiliated Zhongshan Hospital of Dalian University

Dalian, Liaoning, China

Shandong Cancer Hospital

Jinan, Shandong, China

Shanghai Pulmonary Hospital

Shanghai, Shanghai Municipality, China

West China hospital, Sichuan University

Chengdu, Sichuan, China

Key Dates

Start Date

December 16, 2025

Primary Completion Date

December 1, 2028

Completion Date

December 1, 2028

Last Updated

December 19, 2025

Enrollment

ESTIMATED participants

Conditions

Advanced Cancers

Interventions

TQB2922 injection (subcutaneous injection)

DRUG

Contacts

Li Zhang, Doctor

CONTACT

020-87343458 zhangli@sysucc.org.cn

A Clinical Study of TQB3107 Tablets in Patients With Malignant Tumors

NCT06413953

Advanced Cancers

View study

RECRUITINGPHASE1/PHASE2

Plasmodium Immunotherapy for Advanced Cancers

NCT03375983

Advanced Cancers

View study

COMPLETEDPHASE1

Safety Study of GL-ONC1, an Oncolytic Virus, in Patients With Advanced Solid Tumors

NCT00794131

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 19, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Clinical Trial of TQB2922 Injection (Subcutaneous Injection) in Patients With Advanced Cancers

Inclusion Criteria

Exclusion Criteria

A Clinical Study of TQB3107 Tablets in Patients With Malignant Tumors

Plasmodium Immunotherapy for Advanced Cancers

Safety Study of GL-ONC1, an Oncolytic Virus, in Patients With Advanced Solid Tumors

A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors

Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer

Sirolimus or Vorinostat and Hydroxychloroquine in Advanced Cancer